Antihypertensive medication adherence and subsequent healthcare utilization and costs

American Journal of Managed Care

Volumn 16, Issue 8, 2010, Pages 568-576

  Pittman, Donald G ^a   Tao, Zhuliang ^a   Chen, William ^a   Stettin, Glen D ^a  

^a Medco Health Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ANTIHYPERTENSIVE AGENTS; CONFIDENCE INTERVALS; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; HYPERTENSION; INSURANCE CLAIM REVIEW; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 77956119855     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Writing Group Members, Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
2. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356(9246):1955-1964.
3. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290(2):197]. JAMA. 2003;289(19):2560-2572.
4. Chobanian AV. Impact of nonadherence to antihypertensive therapy [editorial]. Circulation. 2009;120(16):1558-1560.
5. Chobanian AV. Shattuck Lecture: the hypertension paradox: more uncontrolled disease despite improved therapy [published correction appears in N Engl J Med. 2009;361(15):1516]. N Engl J Med. 2009;361(9):878-887.
6. Ho PM, Magid DJ, Shetterly SM, et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med. 2008;168(3):271-276.
7. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239-245.
8. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
9. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-1605.
10. Kettani FZ, Dragomir A, Côté R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40(1):213-220.
11. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence, its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-3035.
12. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994;32(3):214-226.
13. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1997;19(6):1446-1457.
14. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
16. Halpem MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039-1048.
17. Zanchetti A. Antihypertensive therapy: how to evaluate the benefits. Am J Cardiol. 1997;79(10A):3-8.
18. Di Martino M, Veronesi C, Degli Esposti L, et al. Adherence to antihypertensive drug treatment and blood pressure control: a real practice analysis in Italy. J Hum Hypertens. 2008;22(1):51-53.
19. Friedman O, McAlister FA, Yun L, Campbell NR, Tu K; Canadian Hypertension Education Program Outcomes Research Taskforce. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario. Am J Med. 2010;123(2):173-181.
20. World Health Organization. Adherence to long-term therapies: evidence for action. http://apps.who.int/medicinedocs/en/d/Js4883e. Accessed November 10, 2009.
21. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12(11):678-683.
22. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
23. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Prac. 2008;62(1):76-87.
24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289(2):178 and 2004;291(18):2196]. JAMA. 2002;288(23):2981-2997.
25. Turnbull F, Neal B, Algert C, et al; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovasuclar events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410-1419.
26. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
27. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich). 2009;11(7):376-382.
28. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-186.
29. Bautista LE. Predictors of persistence with antihypertensive therapy: results from the NHANES. Am J Hypertens. 2008;21(2):183-188.
30. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437-443.